A new blood test has been developed that reads your entire virus history by analysing the antibodies in your bloodstream
Called VirScan it was developed by researchers at Harvard Medical School who insist that once it’s refined it will be cheap enough to mass produce. They estimate it will cost a mere £16 for the average person to take.
It works by analysing blood for antibodies for over 1,000 different strains of 206 human viruses simultaneously.
Because antibodies produced by the immune system to fight viruses stay in the blood stream for many years, the test can produce an accurate history of infections.
Up until now, most tests have revolved around looking for just a single virus. But the brains behind VirScan say it can process 100 samples in two to three days.
“We’ve developed a screening methodology to basically look back in time in people’s [blood] sera and see what they have experienced,” said Dr Stephen Elledge from Harvard Medical School, who led the development team.
“Instead of testing for one individual virus at a time, which is labour intensive, we can assay all these at once. It’s one-stop shopping,” he said.
The Latest on: Blood Test
via Google News
The Latest on: Blood Test
- San Diego Blood Bank Experiencing Critically Low Blood Supply Levelson March 4, 2021 at 3:35 pm
As local hospitals continue to reschedule elective surgeries delayed due to COVID-19 and utilize even more blood for standard surgeries, the San Diego Blood Bank on Thursday put out an urgent call for ...
- Donors needed: Local hospitals face critically low blood supplyon March 4, 2021 at 3:02 pm
San Diego hospitals are facing a critical shortage of blood donations. “We are down to a one or two-day supply of most types,” the blood bank CEO said.
- RI Conducting 2nd Round Of Coronavirus Blood Testson March 4, 2021 at 1:24 pm
The serology testing allows the Rhode Island Department of Health to see what residents have coronavirus antibodies in their blood.
- Agilent to pick up cancer blood tester Resolution Bio in $695M dealon March 4, 2021 at 7:50 am
Diving deeper into the cancer testing market, Agilent Technologies aims to pick up liquid biopsy developer Resolution Bioscience for $550 million in upfront cash.
- Glasgow firm behind pioneering blood test to detect cancer secures seven-figure booston March 4, 2021 at 7:32 am
A Glasgow-based developer of liquid biopsies for the early detection of cancer has reached its round two funding target by securing further investment of more than £1 million – as it eyes Series A ...
- Blood test may predict which COVID-19 patients will become criticalon March 2, 2021 at 1:11 pm
Until recently, there has been no way for doctors to predict how severe a patient's COVID-19 experience would be.
- Blood tests offer early indicator of severe COVID-19on February 26, 2021 at 9:51 am
When patients with COVID-19 arrive in emergency rooms, there are relatively few ways for doctors to predict which ones are more likely to become critically ill and require intensive care and which ...
- Blood tests offer early indicator of severe COVID-19, study sayson February 26, 2021 at 9:06 am
A new study reports that a series of biomarkers associated with white blood cell activation and obesity can predict severe outcomes in COVID-19 patients.
- Blood test for kidney rejection suggests new way to treat post-transplant patientson February 24, 2021 at 11:00 am
Researchers at the University of Pittsburgh School of Medicine have discovered a blood biomarker that predicts kidney transplant rejection with a lead time of about eight months, which could give ...
- Chosen wisely: Grail, Quest team up on cancer blood teston February 23, 2021 at 6:45 am
In a gift to your headline writer, Grail has tapped testing giant Quest Diagnostics to help roll out its upcoming multi-cancer blood test.
via Bing News